Based on these collective prior observations, we sought to understand how dopamine signalling regulates therapy-refractory SCLC progression and to determine whether D2R agonist treatment can inhibit growth of chemotherapy-resistant SCLC by reducing angiogenesis. This evidence concerns the gene DRD2 and small cell lung carcinoma.